Skip to main
  1. Stocks
  2. Precigen
  3. Forecast
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is supported by PAPZIMEOS’s strong commercial momentum, with revenue rising 37% Q/Q to $72.9M in 3Q26 and cumulative revenue reaching $151.4M since its August 2025 approval, while SG&A stayed flat and cash flow turned positive in 3Q26 at $14.8M. The company also benefits from a durable first-mover position in RRP, broad adoption across academic and community centers, and seven years of orphan exclusivity through August 14, 2032, which helps offset near-term competitive noise from VOCERYQ. Beyond the lead asset, the FDA’s September 21, 2026 platform designation for AdenoVerse, plus PRGN-2009 and other pipeline programs, supports longer-term growth and additional value creation.

Bears say

Precigen is exposed to substantial fundamental risk because, aside from PAPZIMEOS, its pipeline remains in clinical development and could face enrollment delays, weaker-than-expected efficacy or safety, and regulatory setbacks if approvals or accelerated pathways are denied. Its history of losses and capital-intensive model heighten balance-sheet pressure, and management may need to raise additional capital under unfavorable terms, which could dilute shareholders and even threaten solvency. Competitive and commercial risks also remain elevated, as INO’s VOCERYQ is approved 10/30 at price parity with a 1Q27 launch, while pricing, scheduling slippage, and patent challenges could limit sales growth and profitability.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Precigen (PGEN) Analyst Forecast & Price Prediction

Get the latest Precigen (PGEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Precigen (PGEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Precigen (PGEN) Analyst Forecast & Price Prediction

Get the latest Precigen (PGEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Precigen (PGEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PGEN stock data and trends